[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100632534":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":28,"centralContacts":32,"locations":42,"responsibleParty":59,"collaborators":63,"id":72,"slug":73,"hasResults":74,"nctId":75,"briefTitle":76,"officialTitle":77,"acronym":24,"eligibilityCriteria":78,"healthyVolunteers":74,"sex":79,"minAge":80,"maxAge":81,"enrollmentInfo":82,"targetDuration":24,"studyType":85,"phases":86,"briefSummary":88,"conditions":89,"keywords":92,"overallStatus":44,"whyStopped":24,"lastUpdateSubmitDate":95,"lastUpdatePostDateStruct":96,"startDateStruct":99,"completionDateStruct":101,"leadSponsor":103,"locationsCount":104},{"fullName":5,"class":6},"Chinese PLA General Hospital","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Venetoclax Combined With CACAG Regimen","EXPERIMENTAL","The entire treatment period for the CACAG+Venetoclax regimen in the trial is 2 week, with a treatment cycle of every 4 weeks, and a total of 2 course of treatment.\n\nChidamide: 30 mg, twice a week, for a total of 4 administrations; Azacitidine: 75 mg\u002Fm\\^2 from day 1 to day 7; Cytarabine (Ara-C): 75-100 mg\u002Fm\\^2 every 12 hours from day 1 to day 7; Aclarubicin: 20 mg\u002Fm\\^2 on days 1, 3, and 5; Recombinant human granulocyte colony-stimulating factor (G-CSF): 300 μg\u002Fday, to be discontinued when neutrophils recover and white blood cell count is ≥20,000\u002FμL; Venetoclax: 100 mg on day 1, 200 mg on day 2, 400 mg from day 3 to day 14, used in combination with azoles, with a reduced dosage of 100 mg\u002Fday.",[13],"Drug: Azacytidine; Cytarabine; Aclacinomycin; Chidamide; Venetoclax; Granulocyte",{"label":15,"type":16,"description":17,"interventionNames":18},"the standard \"3+7\" regimen","ACTIVE_COMPARATOR","IA Regimen:\n\nIdarubicin: 8-12 mg\u002Fm\\^2 on days 1 to 3; Cytarabine (Ara-C): 100 mg\u002Fm\\^2 every 12 hours on days 1 to 7.\n\nOr DA Regimen:\n\nDaunorubicin: 60 mg\u002Fm\\^2 on days 1 to 3; Cytarabine (Ara-C): 100 mg\u002Fm\\^2 every 12 hours on days 1 to 7.\n\nOr MA Regimen:\n\nMitoxantrone: 6-10 mg\u002Fm\\^2 on days 1 to 3; Cytarabine (Ara-C): 100 mg\u002Fm\\^2 every 12 hours on days 1 to 7.",[19],"Drug: the standard \"3+7\" regimen",[21,25],{"type":22,"name":15,"description":17,"armGroupLabels":23,"otherNames":24},"DRUG",[15],null,{"type":22,"name":26,"description":17,"armGroupLabels":27,"otherNames":24},"Azacytidine; Cytarabine; Aclacinomycin; Chidamide; Venetoclax; Granulocyte",[9],[29],{"name":30,"affiliation":5,"role":31},"Dahong Liu, Doctor","STUDY_CHAIR",[33,38],{"name":34,"role":35,"phone":36,"phoneExt":24,"email":37},"Dahong Liu Liu, doctor","CONTACT","+8613681171597","daihongrmg@163.com",{"name":39,"role":35,"phone":40,"phoneExt":24,"email":41},"Liping Dou, Doctor","+8613681207138","lipingruirui@163.com",[43],{"facility":5,"status":44,"city":45,"state":46,"zip":47,"country":48,"countryCode":49,"cosmosGeoPoint":50,"geoPoint":55,"contacts":56},"RECRUITING","Beijing","None Selected","100853","China","CN",{"type":51,"coordinates":52},"Point",[53,54],116.39723,39.9075,{"lat":54,"lon":53},[57],{"name":58,"role":35,"phone":40,"phoneExt":24,"email":41},"Liping Dou",{"type":60,"investigatorFullName":61,"investigatorTitle":62,"investigatorAffiliation":5,"oldNameTitle":24,"oldOrganization":24},"PRINCIPAL_INVESTIGATOR","Daihong Liu","Department of Hematology, The Fifth Medical Center of Chinese PLA General Hospital",[64,66,68,70],{"name":65,"class":6},"940 Hospital of the People's Liberation Army Joint Logistic Support Force",{"name":67,"class":6},"The General Hospital of Western Theater Command",{"name":69,"class":6},"First Affiliated Hospital of Harbin Medical University",{"name":71,"class":6},"960th Hospital of Joint Logistics Support Force of People's Liberation Army of China","100632534","phase-2-venetoclax-azacitidine-in-combination-with-chidamide-and-cag-in-fit-older-patients-with-acute-myeloid-leukaemia-100632534",false,"NCT07514936","Venetoclax-Azacitidine in Combination With Chidamide and CAG in Fit Older Patients With Acute Myeloid Leukaemia","Venetoclax-Azacitidine in Combination With Chidamide and CAG Versus Daunorubicin and Cytarabine in Fit Older Patients With Acute Myeloid Leukaemia：A Multicenter, Randomized, Controlled, Phase 3 Trial","Inclusion Criteria:\n\n1. Voluntary participation in the clinical study; the subject or legal guardian fully understands and is informed about the study and has signed the Informed Consent Form (ICF); willing to follow and able to complete all trial procedures;\n2. Age between 60-75 years at the time of screening, with no gender restrictions;\n3. Patients are newly diagnosed with AML, and the diagnosis conforms to the standards of the Chinese Medical Association 2021 edition;\n4. No severe allergic constitution;\n5. Liver function: ALT and AST \\\u003C= 2.5 times the upper limit of normal values, bilirubin \\\u003C= 2 times the upper limit of normal values;\n6. Renal function: creatinine \\\u003C= upper limit of normal values;\n7. No uncontrollable infections or severe mental illnesses;\n8. Performance status score is 0-3 (ECOG), with an expected survival of at least 4 months.\n\nExclusion Criteria:\n\n1. Patients who are allergic to the study medication or have contraindications to it;\n2. Pregnant or breastfeeding women;\n3. Patients with active infections;\n4. Patients with long-term smoking or alcohol abuse that could affect the evaluation of trial results;\n5. Patients with mental disorders or other conditions that prevent obtaining informed consent, or who are unable to cooperate with the treatment and examination procedures;\n6. Patients who have undergone major organ surgery within the last 6 weeks;\n7. Abnormal liver function, with total bilirubin \\> 1.5 times the upper limit of normal, ALT\u002FAST \\> 2.5 times the upper limit of normal, or liver-infiltrated patients with ALT\u002FAST \\> 5 times the upper limit of normal; abnormal renal function, with serum creatinine \\> 1.5 times the upper limit of normal;\n8. Patients whom the investigator deems unsuitable for this clinical trial (e.g., poor compliance, drug abuse, etc.).","ALL","60 Years","75 Years",{"count":83,"type":84},120,"ESTIMATED","INTERVENTIONAL",[87],"PHASE2","This study is a multicenter, prospective, randomized, controlled clinical trial, observing the efficacy and safety of the CACAG+Venetoclax regimen (Chidamide + Azacitidine + Aclarubicin + Cytarabine + Recombinant Human Granulocyte Colony-Stimulating Factor + Venetoclax) in elderly patients with newly diagnosed Acute Myeloid Leukemia (AML). The control group applies the standard \"3+7\" regimen. The aim is to improve the remission rate of AML patients, reduce the probability of adverse events, and thereby improve patient prognosis and extend patient survival.",[90,91],"Newly Diagnosed Acute Myeloid Leukemia (AML)","Elderly Patients",[91,93,94],"newly diagnosed","Acute Myeloid Leukemia","2026-06-11",{"date":97,"type":98},"2026-06-15","ACTUAL",{"date":100,"type":98},"2024-11-18",{"date":102,"type":84},"2027-12-31",{"name":5,"class":6},1]